LENZ Therapeutics, Inc. Stock OTC Markets
Stocks
GRPH
US52635N1037
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 162M 142M 131M 121M 228M 15.64B 233M 1.57B 616M 7.66B 610M 597M 26.37B | P/E 2026 * |
-1.15x | P/E 2027 * | -1.51x |
|---|---|---|---|---|---|
| Enterprise Value | 162M 142M 131M 121M 228M 15.64B 233M 1.57B 616M 7.66B 610M 597M 26.37B | EV / Sales 2026 * |
8.69x | EV / Sales 2027 * | 2.57x |
| Free-Float |
97.35% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: LENZ Therapeutics, Inc.
| 1 day | -2.75% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.75% | -4.79% | - | - | 162M | |
| +0.24% | -1.54% | +52.85% | +60.31% | 53.83B | |
| -7.17% | -4.39% | +42.72% | +73.70% | 52.1B | |
| +0.80% | -6.31% | +5.62% | +413.12% | 23.48B | |
| -0.09% | -0.01% | -16.85% | -16.17% | 23.13B | |
| +4.00% | +3.00% | +37.29% | -4.97% | 19.36B | |
| -1.14% | +0.03% | +31.67% | -31.21% | 17.56B | |
| -5.16% | -7.00% | +168.44% | +291.24% | 15.2B | |
| +6.81% | +2.88% | +37.31% | +665.31% | 14.83B | |
| +0.43% | -1.03% | +25.75% | +186.18% | 14.06B | |
| Average | -0.43% | -2.62% | +42.75% | +181.95% | 25.95B | |
| Weighted average by Cap. | -1.12% | -2.36% | +40.96% | +139.92% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 18.7M 16.34M 15.08M 13.9M 26.19M 1.8B 26.78M 180M 70.88M 882M 70.22M 68.68M 3.04B | 63.18M 55.21M 50.95M 46.96M 88.52M 6.08B 90.48M 609M 240M 2.98B 237M 232M 10.26B |
| Net income | -142M -124M -114M -105M -198M -13.63B -203M -1.36B -537M -6.68B -532M -520M -22.98B | -111M -96.77M -89.29M -82.31M -155M -10.66B -159M -1.07B -420M -5.22B -416M -407M -17.98B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
